Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran’s Fate Remains Unclear
Efanesoctocog Alfa Filed Last Month
Executive Summary
Sanofi is hoping to have two paradigm-changing hemophilia drugs on the market by 2025 – but one of these, fitusiran, must first prove its safety and efficacy at a lower dose.
You may also be interested in...
Alnylam Stays Mum On APOLLO-B Amid Anticipation Over Major Readout
The company announced a respectable increase in second quarter sales and expects to announce topline results within the next three weeks for the Phase III trial of Onpattro in ATTR-CM.
Japan-Specific Approval For Hemlibra In Acquired Hemophilia A
Hemlibra receives new approval in Japan intractable disease indication, while positive Phase III results in mild/moderate disease hemophilia A will support a planned EU filing in this setting.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.